Flemming Ørnskov
Flemming Ørnskov is the CEO of Galderma, a global dermatology company that has gained attention for its innovative biopharmaceuticals, including the recently approved therapeutic drug Nemluvio. Ørnskov has a strong background in the pharmaceutical industry, having previously held leadership roles at Shire, and is focused on successfully bringing new treatments to market while navigating the complexities of a rapidly evolving healthcare landscape.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Guatemala | 1 | 8.00 | 0.09% | +0% | 17,915,568 | 16,558 | $82,000 | 76$ |
| Totals | 1 | 17,915,568 | 16,558 | $82,000 | 76$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Flemming Ørnskov is the CEO of Galderma and has high expectations for the new drug Nemluvio.
7